Daily Anesthesiology Research Analysis
Today’s top anesthesiology-related research advances span trauma coagulopathy mechanisms, opioid stewardship in chronic pain, and innovations in awake airway management. A mechanistic study links truncated, hyperactive ADAMTS13 to hyperfibrinolysis and mortality after trauma, while a rigorous meta-analysis shows tramadol’s small analgesic benefit is likely outweighed by increased adverse events. A randomized comparison supports supraglottic airway–assisted awake intubation as a viable alternativ
Summary
Today’s top anesthesiology-related research advances span trauma coagulopathy mechanisms, opioid stewardship in chronic pain, and innovations in awake airway management. A mechanistic study links truncated, hyperactive ADAMTS13 to hyperfibrinolysis and mortality after trauma, while a rigorous meta-analysis shows tramadol’s small analgesic benefit is likely outweighed by increased adverse events. A randomized comparison supports supraglottic airway–assisted awake intubation as a viable alternative to video laryngoscopy and flexible bronchoscopy.
Research Themes
- Trauma-induced hyperfibrinolysis mechanisms and antifibrinolytic strategies
- Reassessing tramadol for chronic pain: benefit-harm balance
- Awake airway management: supraglottic devices vs video/fiberoptic approaches
Selected Articles
1. A novel role for ADAMTS13 in hyperfibrinolysis after trauma-induced shock
In 39 trauma patients with shock, 23% exhibited truncated, hyperactive ADAMTS13, which correlated with profound hyperfibrinolysis and higher mortality. In vitro, tPA/plasmin truncated and activated ADAMTS13, an effect preventable by tranexamic acid, implicating ADAMTS13 as a direct driver of hyperfibrinolysis.
Impact: This study links a defined ADAMTS13 conformation to hyperfibrinolysis and mortality and provides a mechanistic rationale for antifibrinolytic therapy. It reframes trauma-induced coagulopathy by implicating ADAMTS13 as an actionable target.
Clinical Implications: Early recognition of hyperactivated ADAMTS13 could refine antifibrinolytic use (e.g., tranexamic acid) and patient stratification in trauma. Development of rapid assays for ADAMTS13 conformation/activity could guide resuscitation strategies.
Key Findings
- Truncated, hyperactive ADAMTS13 was detected in 23% of trauma-shock patients.
- This phenotype associated with severe hyperfibrinolysis (FIBTEM ML 85% vs 1%; P=0.002) and higher mortality (44% vs 3%; P=0.007).
- tPA/plasmin truncated and activated ADAMTS13 in vitro in a concentration-dependent manner; tranexamic acid prevented this activation.
- Hyperactivated ADAMTS13 directly contributed to hyperfibrinolysis in ROTEM and fibrin assays.
Methodological Strengths
- Integrated clinical cohort data with mechanistic in vitro experiments.
- Objective hemostatic phenotyping using ROTEM FIBTEM and fibrin formation assays.
Limitations
- Single-center study with a small trauma cohort (n=39).
- Observational clinical component limits causal inference and lacks interventional validation.
Future Directions: Develop rapid bedside assays for ADAMTS13 conformation/activity and test targeted antifibrinolytic or ADAMTS13-modulating strategies in prospective multicenter trials.
BACKGROUND: Trauma-induced coagulopathy with hyperfibrinolysis is associated with high mortality. The protease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs 13) is cleaved after tissue injury. We analysed the underlying mechanism of ADAMTS13 proteolytic cleavage and the effect of ADAMTS13 on trauma-induced hyperfibrinolysis. METHODS: Thirty-nine trauma patients with shock were stratified based on ADAMTS13 conformation. Mechanisms of ADAMTS13 cleavage were explored in vitro using blood from healthy volunteers. The role of ADAMTS13 in hyperfibrinolysis was examined using rotational thromboelastometry (ROTEM) and a fibrin formation assay. RESULTS: ADAMTS13 circulated in a truncated and hyperactive form in 23% of trauma patients in shock. Truncated ADAMTS13 was associated with a significant increase in hyperfibrinolysis (ROTEM FIBTEM maximum lysis 85 [62-100] vs 1 [0-7]%, P=0.002) and mortality (44% vs 3%, P=0.007) compared with patients with a closed ADAMTS13 conformation. In vitro, ADAMTS13 was cleaved at its distal self-regulating domains in the presence of tissue plasminogen activator and plasmin, which concentration-dependently increased ADAMTS13 activity. This activation was prevented by tranexamic acid. Hyperactivated ADAMTS13 was associated with hyperfibrinolysis by both ROTEM and fibrin formation assays compared with conditions where ADAMTS13 was inactivated. CONCLUSIONS: During trauma-induced shock, ADAMTS13 can circulate in a truncated and hyperactivated conformation, which is associated with hyperfibrinolysis and mortality. In vitro, tissue plasminogen activator and plasmin can truncate ADAMTS13, increasing its activity. Additionally, ADAMTS13 directly contributes to hyperfibrinolysis, and tranexamic acid can prevent ADAMTS13 degradation. INSTITUTIONAL ETHICAL REVIEW BOARD APPROVAL NUMBERS: NL58766.018.16, NL74188.018.20.
2. Tramadol versus placebo for chronic pain: a systematic review with meta-analysis and trial sequential analysis.
Across 19 RCTs (n=6,506), tramadol reduced pain by 0.93 NRS points—below the prespecified minimal important difference—while increasing serious adverse events (OR 2.13) and multiple non-serious adverse events. The benefit-harm balance disfavors tramadol for chronic pain management.
Impact: Provides rigorous, contemporary evidence with TSA and GRADE that challenges routine tramadol use for chronic pain by quantifying limited efficacy and increased harms.
Clinical Implications: Prefer non-opioid multimodal strategies for chronic pain; if tramadol is considered, counsel on small benefit, monitor for serious AEs, and limit duration. Reassess formularies and prescribing pathways in perioperative and pain clinics.
Key Findings
- 19 RCTs (n=6,506) showed tramadol reduced pain by −0.93 NRS points (below minimal important difference).
- Serious adverse events increased with tramadol (OR 2.13; 97.5% CI 1.29–3.51), driven by cardiac events and neoplasms.
- Non-serious adverse events increased: nausea (NNH 7), dizziness (NNH 8), constipation (NNH 9), somnolence (NNH 13).
- Quality-of-life data were insufficient for meta-analysis; overall risk of bias was high across outcomes.
Methodological Strengths
- Use of Trial Sequential Analysis (TSA) and GRADE to assess robustness and certainty.
- Comprehensive search across major databases with explicit risk-of-bias assessment.
Limitations
- High risk of bias in included trials and heterogeneity in outcomes.
- Insufficient data on quality of life, dependence, abuse, and long-term safety.
Future Directions: Head-to-head, high-quality RCTs versus non-opioid regimens with long-term follow-up, and stratified analyses to identify subgroups (if any) with meaningful benefit.
OBJECTIVES: The objective of our study was to assess the benefits and harms of tramadol vs placebo in adults with chronic pain. DESIGN: The research method was a systematic review of randomised clinical trials with meta-analysis. The review followed the Trial Sequential Analysis and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. DATA SOURCES: The Cochrane Library, MEDLINE, Embase, Science Citation Index and BIOSIS were searched for trials published from inception to 6 February 2025. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Studies were eligible for inclusion if they were published and unpublished randomised clinical trials comparing tramadol vs placebo in adults with any type of chronic pain. Risk of bias was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions. MAIN OUTCOME MEASURES: The main outcome measures were pain level, adverse events, quality of life, dependence, abuse and depressive symptoms. RESULTS: We included 19 randomised placebo-controlled clinical trials enrolling 6506 participants. All outcome results were at high risk of bias. Meta-analysis and Trial Sequential Analysis showed evidence of a beneficial effect of tramadol on chronic pain (mean difference numerical rating scale (NRS) -0.93 points; 97.5% CI -1.26 to -0.60; p<0.0001; low certainty of evidence). However, the effect size was below our predefined minimal important difference of 1.0 point on NRS. Beta binomial regression showed evidence of a harmful effect of tramadol on serious adverse events (OR 2.13; 97.5% CI 1.29 to 3.51; p=0.001; moderate certainty of evidence), mainly driven by a higher proportion of cardiac events and neoplasms. It was not possible to conduct a meta-analysis of the quality of life due to a lack of data. Meta-analysis and Trial Sequential Analysis showed that tramadol increased the risk of several non-serious adverse events including nausea (number needed to harm (NNH) 7), dizziness (NNH 8), constipation (NNH 9), and somnolence (NNH 13) (all very low certainty of evidence). CONCLUSION: Tramadol may have a slight effect on reducing chronic pain levels (low certainty of evidence) while likely increasing the risk of both serious (moderate certainty of evidence) and non-serious adverse events (very low certainty of evidence). The potential harms associated with tramadol use for pain management likely outweigh its limited benefits.
3. Supraglottic airway devices in awake tracheal intubation: a viable alternative to fiberoptic and video laryngoscopy.
In this randomized comparative study, awake intubation using a supraglottic airway achieved similar success and complication rates to video laryngoscopy and flexible bronchoscopy, with intermediate imaging and intubation times. The technique allows continuous oxygenation and tidal volume monitoring during the procedure.
Impact: Expands the armamentarium for awake difficult-airway management by validating a supraglottic conduit approach against standard techniques.
Clinical Implications: Consider supraglottic airway–guided awake intubation when continuous oxygenation and ventilation monitoring are prioritized or when fiberoptic expertise/equipment is limited.
Key Findings
- Awake supraglottic airway technique had comparable success and complication rates to video laryngoscopy and flexible bronchoscopy.
- Mean vocal cord imaging time (74.93 ± 55 s) and intubation time (210.0 ± 120 s) were between video laryngoscopy (faster) and fiberoptic bronchoscopy (slower).
- Supraglottic approach enabled continuous oxygenation and tidal volume monitoring throughout the procedure.
Methodological Strengths
- Prospective randomized comparative design with three active techniques.
- Registered trial with clinically relevant procedural endpoints.
Limitations
- Single-center study; sample size not reported in abstract.
- Blinding unlikely; oxygenation and time metrics may be operator-dependent.
Future Directions: Multicenter RCTs powered for hypoxemia events and patient-centered outcomes; cost-effectiveness and training curve analyses across skill levels.
BACKGROUND: Awake tracheal intubation is advised for patients with known difficult airways. While flexible bronchoscopy is the conventional technique, video laryngoscopy offers faster intubation. Recent studies reveal that supraglottic airway devices can also be effectively used for awake intubation; however, few investigations compare their effectiveness with that of flexible bronchoscopy and video laryngoscopy. This study aims to compare the effectiveness of these three. methods: flexible bronchoscopy, video laryngoscopy, and awake tracheal intubation using supraglottic airway devices. METHODS: Patients were divided into three groups: fiberoptic bronchoscopy, video laryngoscopy, and supraglottic airway groups. All patients received RESULTS: Success and complication rates were similar across groups. The supraglottic airway group had a mean vocal cord imaging time of 74.93 ± 55 s, longer than video laryngoscopy but shorter than fiberoptic bronchoscopy. Intubation times were longer for the supraglottic airway group (210.0 ± 120 s) than for video laryngoscopy but shorter than fiberoptic bronchoscopy. CONCLUSION: The awake supraglottic airway technique offers advantages over traditional awake intubation methods, including the ability to monitor tidal volume and maintain continuous oxygenation throughout the procedure. This technique achieves comparable success rates, intubation times, and complication rates to video laryngoscopy and fiberoptic bronchoscopy, making it a reliable alternative for difficult airways. TRIAL REGISTRATION: https://clinicaltrials.gov (NCT06279416, registered on 19.02.2024). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12871-025-03331-4.